News
Moderna, FDA and Covid
Digest more
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Arboviruses are spreading beyond tropical and subtropical regions due to climate change, population growth, and increased ...
The Food and Drug Administration Thursday granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...
Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...
On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results